Capricor Therapeutics (CAPR) Total Non-Current Liabilities (2011 - 2026)

Capricor Therapeutics' Total Non-Current Liabilities history runs 16 years deep, the most recent figure standing at $13.9 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 268.52% year-over-year to $13.9 million; the TTM figure through Mar 2026 stood at $13.9 million (up 268.52% YoY), while the FY2025 annual figure was $14.3 million, up 258.68% from the prior year.
• Total Non-Current Liabilities was $13.9 million for Q1 2026 at Capricor Therapeutics, down from $14.3 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $26.0 million in Q1 2022 to a low of $194603.0 in Q2 2025.
• Historically, Total Non-Current Liabilities has averaged $10.0 million across 5 years, with a median of $8.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities soared 660.79% in 2022, then tumbled 95.6% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $14.7 million in 2022, then sank by 66.97% to $4.9 million in 2023, then decreased by 17.9% to $4.0 million in 2024, then jumped by 258.68% to $14.3 million in 2025, then declined by 2.63% to $13.9 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $13.9 million (Q1 2026), $14.3 million (Q4 2025), and $14.4 million (Q3 2025), per Business Quant data.